BioRock Ventures Name

PTM Therapeutics develops therapies targeting chronic diseases and cancer. It employs post-translational modification technology to differentiate healthy from diseased cells, enabling pharmaceutical developers to discover targets and develop new therapeutics.

Veana Therapeutics is a biotechnology company based in Portland, Oregon. Founded in 2012, it specializes in developing immunotherapeutic products for cancer treatment using its proprietary TEA-based technologies. The company's approach involves creating bioavailable anti-cancer agents that simultaneously kill tumor cells and stimulate the immune system.

Octagon Therapeutics is a preclinical-stage biopharmaceutical company developing targeted immunomodulator medicines for chronic autoimmune and inflammatory diseases. Incorporated in 2016, the company is based in Cambridge, Massachusetts.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

Primmune Therapeutics is a biotechnology company developing orally administered small molecule toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy. The TLR7 agonists aim to activate systemic innate immune responses, promoting cytokine and chemokine production, NK cell activation, and B-cell proliferation to support anti-tumor activity. The company intends to combine these agents with adaptive cancer therapies such as checkpoint inhibitors to improve response rates and durability, and targets metastatic cancers.

Primmune Therapeutics is a biotechnology company developing orally administered small molecule toll-like receptor 7 (TLR7) agonists to stimulate innate immunity in cancer immunotherapy. The TLR7 agonists aim to activate systemic innate immune responses, promoting cytokine and chemokine production, NK cell activation, and B-cell proliferation to support anti-tumor activity. The company intends to combine these agents with adaptive cancer therapies such as checkpoint inhibitors to improve response rates and durability, and targets metastatic cancers.

Seal Rock Therapeutics develops small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company focuses on treating hepatic indications like NASH, with additional opportunities in cardiac, immunological, and neurodegenerative areas.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.